Haploidentical donor transplants for severe aplastic anemia

Area of Science:

• Hematology
• Immunology
• Transplantation Medicine

Background:

• Haploidentical stem cell transplantation (HAPLO) is an emerging option for acquired severe aplastic anemia.
• Graft rejection and graft-versus-host disease (GvHD) are significant challenges in HAPLO.

Purpose of the Study:

• To review the current status and outcomes of HAPLO grafts in acquired severe aplastic anemia.
• To discuss strategies for overcoming transplant-related complications.

Main Methods:

• Review of published reports on HAPLO for acquired severe aplastic anemia.
• Analysis of conditioning regimens, graft sources, graft manipulation, and GvHD prophylaxis strategies.
• Inclusion of data on mesenchymal stem cell use.

Main Results:

• Data from 375 patients reviewed.
• Average graft rejection rate of 6%.
• Grade II-IV GvHD observed in 23% of patients.
• 1-year survival rate of 80%.

Conclusions:

• HAPLO transplantation offers encouraging results for acquired severe aplastic anemia, particularly in younger populations.
• Various strategies, including T-cell depletion and post-transplant cyclophosphamide, improve HAPLO outcomes.
• HAPLO transplant is a viable alternative donor option for acquired aplastic anemia.